Loading…
Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia
Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from Janu...
Saved in:
Published in: | Journal of antimicrobial chemotherapy 2007-03, Vol.59 (3), p.525-530 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543 |
---|---|
cites | cdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543 |
container_end_page | 530 |
container_issue | 3 |
container_start_page | 525 |
container_title | Journal of antimicrobial chemotherapy |
container_volume | 59 |
creator | Kwon, Ki Tae Oh, Won Sup Song, Jae-Hoon Chang, Hyun-Ha Jung, Sook-In Kim, Shin-Woo Ryu, Seong Yeol Heo, Sang Taek Jung, Dong Sik Rhee, Ji-Young Shin, Sang Yop Ko, Kwan Soo Peck, Kyong Ran Lee, Nam Yong |
description | Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P < 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P < 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P < 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy. |
doi_str_mv | 10.1093/jac/dkl499 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70202552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkl499</oup_id><sourcerecordid>1317815101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</originalsourceid><addsrcrecordid>eNqF0U1rFTEUBuAgFnutbvwBEgRdCNPmO5NlLdYWLnTTQnETMpkEczszGZMMtf_elLl4wYWuzubhTc55AXiH0SlGip7tjD3rHwam1AuwwUyghiCFX4INoog3knF6DF7nvEMICS7aV-AYS4IpEXwD7q7H2dgCo4dhDLOb3AiTyyEXM1kH4wTHmIoZQnmCYYKzKcFNJcPHUH7AcxsmV2JXA1yC6zBuDOYNOPJmyO7tfp6Au8uvtxdXzfbm2_XF-baxTMrSSEJaXn_SK-Mp4Uz2hmEllcNIKs-l99L3qvOyZ4ga1PasY6KzxFKPpeKMnoBPa-6c4s_F5aLHkK0bBjO5uGQtEUGEc_JfiBUXgklU4Ye_4C4uaapLaIKlaDESz2mfV2RTzDk5r-cURpOeNEb6uRJdK9FrJRW_3ycu3ej6A913UMHHPTDZmsGnevmQD64VRFDeHlxc5n8_2Kyuluh-_ZEmPWghqeT66v67vt9-UYJxpS_pbxS5r18</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217681062</pqid></control><display><type>article</type><title>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</title><source>Oxford Journals Online</source><creator>Kwon, Ki Tae ; Oh, Won Sup ; Song, Jae-Hoon ; Chang, Hyun-Ha ; Jung, Sook-In ; Kim, Shin-Woo ; Ryu, Seong Yeol ; Heo, Sang Taek ; Jung, Dong Sik ; Rhee, Ji-Young ; Shin, Sang Yop ; Ko, Kwan Soo ; Peck, Kyong Ran ; Lee, Nam Yong</creator><creatorcontrib>Kwon, Ki Tae ; Oh, Won Sup ; Song, Jae-Hoon ; Chang, Hyun-Ha ; Jung, Sook-In ; Kim, Shin-Woo ; Ryu, Seong Yeol ; Heo, Sang Taek ; Jung, Dong Sik ; Rhee, Ji-Young ; Shin, Sang Yop ; Ko, Kwan Soo ; Peck, Kyong Ran ; Lee, Nam Yong</creatorcontrib><description>Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P < 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P < 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P < 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkl499</identifier><identifier>PMID: 17213265</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Acinetobacter ; Acinetobacter Infections - drug therapy ; Adult ; Aged ; Anti-Bacterial Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; attributable mortality ; Bacteremia - drug therapy ; Bacteremia - mortality ; Bacteria ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Cohort Studies ; discordant antimicrobial therapy ; Drug resistance ; Drug Resistance, Bacterial ; Drug therapy ; Female ; Hospitals ; Human bacterial diseases ; Humans ; Imipenem - pharmacology ; Imipenem - therapeutic use ; Infections ; Infectious diseases ; Male ; matched cohort study ; Medical sciences ; Middle Aged ; Mortality ; Multivariate Analysis ; Pharmacology. Drug treatments ; Retrospective Studies</subject><ispartof>Journal of antimicrobial chemotherapy, 2007-03, Vol.59 (3), p.525-530</ispartof><rights>The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2007</rights><rights>2007 INIST-CNRS</rights><rights>The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</citedby><cites>FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18626358$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17213265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, Ki Tae</creatorcontrib><creatorcontrib>Oh, Won Sup</creatorcontrib><creatorcontrib>Song, Jae-Hoon</creatorcontrib><creatorcontrib>Chang, Hyun-Ha</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Kim, Shin-Woo</creatorcontrib><creatorcontrib>Ryu, Seong Yeol</creatorcontrib><creatorcontrib>Heo, Sang Taek</creatorcontrib><creatorcontrib>Jung, Dong Sik</creatorcontrib><creatorcontrib>Rhee, Ji-Young</creatorcontrib><creatorcontrib>Shin, Sang Yop</creatorcontrib><creatorcontrib>Ko, Kwan Soo</creatorcontrib><creatorcontrib>Peck, Kyong Ran</creatorcontrib><creatorcontrib>Lee, Nam Yong</creatorcontrib><title>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P < 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P < 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P < 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.</description><subject>Acinetobacter</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>attributable mortality</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - mortality</subject><subject>Bacteria</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>discordant antimicrobial therapy</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Hospitals</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Imipenem - pharmacology</subject><subject>Imipenem - therapeutic use</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>matched cohort study</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqF0U1rFTEUBuAgFnutbvwBEgRdCNPmO5NlLdYWLnTTQnETMpkEczszGZMMtf_elLl4wYWuzubhTc55AXiH0SlGip7tjD3rHwam1AuwwUyghiCFX4INoog3knF6DF7nvEMICS7aV-AYS4IpEXwD7q7H2dgCo4dhDLOb3AiTyyEXM1kH4wTHmIoZQnmCYYKzKcFNJcPHUH7AcxsmV2JXA1yC6zBuDOYNOPJmyO7tfp6Au8uvtxdXzfbm2_XF-baxTMrSSEJaXn_SK-Mp4Uz2hmEllcNIKs-l99L3qvOyZ4ga1PasY6KzxFKPpeKMnoBPa-6c4s_F5aLHkK0bBjO5uGQtEUGEc_JfiBUXgklU4Ye_4C4uaapLaIKlaDESz2mfV2RTzDk5r-cURpOeNEb6uRJdK9FrJRW_3ycu3ej6A913UMHHPTDZmsGnevmQD64VRFDeHlxc5n8_2Kyuluh-_ZEmPWghqeT66v67vt9-UYJxpS_pbxS5r18</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>Kwon, Ki Tae</creator><creator>Oh, Won Sup</creator><creator>Song, Jae-Hoon</creator><creator>Chang, Hyun-Ha</creator><creator>Jung, Sook-In</creator><creator>Kim, Shin-Woo</creator><creator>Ryu, Seong Yeol</creator><creator>Heo, Sang Taek</creator><creator>Jung, Dong Sik</creator><creator>Rhee, Ji-Young</creator><creator>Shin, Sang Yop</creator><creator>Ko, Kwan Soo</creator><creator>Peck, Kyong Ran</creator><creator>Lee, Nam Yong</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070301</creationdate><title>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</title><author>Kwon, Ki Tae ; Oh, Won Sup ; Song, Jae-Hoon ; Chang, Hyun-Ha ; Jung, Sook-In ; Kim, Shin-Woo ; Ryu, Seong Yeol ; Heo, Sang Taek ; Jung, Dong Sik ; Rhee, Ji-Young ; Shin, Sang Yop ; Ko, Kwan Soo ; Peck, Kyong Ran ; Lee, Nam Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acinetobacter</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>attributable mortality</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - mortality</topic><topic>Bacteria</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>discordant antimicrobial therapy</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Hospitals</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Imipenem - pharmacology</topic><topic>Imipenem - therapeutic use</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>matched cohort study</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, Ki Tae</creatorcontrib><creatorcontrib>Oh, Won Sup</creatorcontrib><creatorcontrib>Song, Jae-Hoon</creatorcontrib><creatorcontrib>Chang, Hyun-Ha</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Kim, Shin-Woo</creatorcontrib><creatorcontrib>Ryu, Seong Yeol</creatorcontrib><creatorcontrib>Heo, Sang Taek</creatorcontrib><creatorcontrib>Jung, Dong Sik</creatorcontrib><creatorcontrib>Rhee, Ji-Young</creatorcontrib><creatorcontrib>Shin, Sang Yop</creatorcontrib><creatorcontrib>Ko, Kwan Soo</creatorcontrib><creatorcontrib>Peck, Kyong Ran</creatorcontrib><creatorcontrib>Lee, Nam Yong</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, Ki Tae</au><au>Oh, Won Sup</au><au>Song, Jae-Hoon</au><au>Chang, Hyun-Ha</au><au>Jung, Sook-In</au><au>Kim, Shin-Woo</au><au>Ryu, Seong Yeol</au><au>Heo, Sang Taek</au><au>Jung, Dong Sik</au><au>Rhee, Ji-Young</au><au>Shin, Sang Yop</au><au>Ko, Kwan Soo</au><au>Peck, Kyong Ran</au><au>Lee, Nam Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>59</volume><issue>3</issue><spage>525</spage><epage>530</epage><pages>525-530</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P < 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P < 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P < 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>17213265</pmid><doi>10.1093/jac/dkl499</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7453 |
ispartof | Journal of antimicrobial chemotherapy, 2007-03, Vol.59 (3), p.525-530 |
issn | 0305-7453 1460-2091 |
language | eng |
recordid | cdi_proquest_miscellaneous_70202552 |
source | Oxford Journals Online |
subjects | Acinetobacter Acinetobacter Infections - drug therapy Adult Aged Anti-Bacterial Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents attributable mortality Bacteremia - drug therapy Bacteremia - mortality Bacteria Bacterial diseases Bacterial sepsis Biological and medical sciences Cohort Studies discordant antimicrobial therapy Drug resistance Drug Resistance, Bacterial Drug therapy Female Hospitals Human bacterial diseases Humans Imipenem - pharmacology Imipenem - therapeutic use Infections Infectious diseases Male matched cohort study Medical sciences Middle Aged Mortality Multivariate Analysis Pharmacology. Drug treatments Retrospective Studies |
title | Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A49%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20imipenem%20resistance%20on%20mortality%20in%20patients%20with%20Acinetobacter%20bacteraemia&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Kwon,%20Ki%20Tae&rft.date=2007-03-01&rft.volume=59&rft.issue=3&rft.spage=525&rft.epage=530&rft.pages=525-530&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkl499&rft_dat=%3Cproquest_cross%3E1317815101%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217681062&rft_id=info:pmid/17213265&rft_oup_id=10.1093/jac/dkl499&rfr_iscdi=true |